Research programme: antifibrinolytic therapeutics - Edge TherapeuticsAlternative Names: EG-1963
Latest Information Update: 22 Dec 2015
At a glance
- Originator Edge Therapeutics
- Mechanism of Action Antifibrinolytic agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Surgical blood loss
Most Recent Events
- 22 Dec 2015 Early research in Surgical blood loss in USA (Topical)